您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Calcitriol(1,25-Dihydroxyvitamin D3)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Calcitriol(1,25-Dihydroxyvitamin D3)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Calcitriol(1,25-Dihydroxyvitamin D3)图片
CAS NO:32222-06-3
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)416.64
FormulaC27H44O3
CAS No.32222-06-3
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 83 mg/mL (199.2 mM)
Water: <1 mg/mL
Ethanol: 83 mg/mL (199.2 mM)
Other info

Chemical Name: 1α,25-Dihydroxyvitamin D3

InChi Key: GMRQFYUYWCNGIN-GSMZWGLTSA-N

InChi Code: InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24?,25-,27-/m1/s1

SMILES Code: O[C@H](C/C1=C/C=C2C3CC[C@@H]([C@]3(CCC/2)C)[C@H](C)CCCC(C)(O)C)C[C@@H](O)C1=C

Synonyms1,25(OH)2D3; 1,25(OH)2-D3; 1,25(OH)2-VD3; 1,25-Dihydroxyvitamin D3; RO215535, Topitriol; Rocaltrol; Calcijex; Topitriol; Silkis; Soltriol; 1α,25-Dihydroxyvitamin D3; 1α,25(OH)2D3
实验参考方法
In Vitro

In vitro activity: Calcitriol is a potent inhibitor of PHA-induced lymphocyte proliferation, achieving 70% inhibition of tritiated thymidine incorporation after 72 h in culture. Calcitriol suppresses interleukin-2 (IL-2) production by PHA-stimulated peripheral blood mononuclear cells in a concentration-dependent fashion. Calcitriol increases the concentration of intracellular calcium ([Ca2+]i) within 5 s by mobilizing calcium from the endoplasmic reticulum and the formation of inositol 1,4, 5-trisphosphate and diacylglycerol. Calcitriol can inhibit the proliferation and promote the differentiation of human prostate adenocarcinoma cells. Calcitriol causes a selective decrease in the secreted levels of type IV collagenases (MMP-2 and MMP-9). Calcitriol has antiproliferative activity in squamous cell carcinoma and prostatic adenocarcinoma and enhances the antitumor activity of platinum-based agents. Calcitriol prior to paclitaxel significantly reduces clonogenic survival compared with either agent alone in the murine squamous cell carcinoma and PC-3 cells. Calcitriol is a potent anti-proliferative agent in a wide variety of malignant cell types. Calcitriol effects are associated with an increase in G0/G1 arrest, induction of apoptosis and differentiation, modulation of expression of growth factor receptors. Calcitriol potentiates the antitumor effects of many cytotoxic agents and inhibits motility and invasiveness of tumor cells and formation of new blood vessels.


Cell Assay: HeLa S3 cells are plated at a density of 1,000 cells/well in 96-well plates of Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), treated with 1% ethanol (control) or various concentrations of Calcitriol (100, 200, and 500 nM) for 72 h. A Cell Counting Kit8 (CCK-8) is used to determine cell proliferation. At 24, 48, 72, 96, 120, and 144 h after culturing with 200 nM Calcitriol, cells are harvested for analysis. Three independent experiments are performed in quadruplicate

In VivoChronic treatment with Calcitriol (150 ng/kg per day for 4.5 months) improves the relaxations (pD2: 6.30±0.09, Emax: 68.6±3.9% in Calcitriol-treated OVX, n=8). Renal blood flow in OVX rats is reduced in both kidneys, and the flow is restored by Calcitriol treatment. The increased expression of COX-2 and Thromboxane-prostanoid (TP) receptor in OVX rat renal arteries is reduced by chronic calcitriol administration[3]. High- and low-dose Calcitriol treatment significantly decreases the systolic blood pressure (SBP) in the fructose-fed rats by 14±4 and 9±4 mmHg, respectively, at Day 56. High-dose Calcitriol treatment (20 ng/kg per day) significantly increases serum ionized calcium level (1.44±0.05 mmol/L) compare with the other groups.
Animal modelAdult female Sprague-Dawley rats
Formulation & Dosage150 ng/kg daily, oral gavage
ReferencesJ Clin Invest. 1984 Oct;74(4):1451-5; J Biol Chem. 1997 May 2;272(18):11902-7; Cancer Epidemiol Biomarkers Prev. 1997 Sep;6(9):727-32.